Association of Bicarbonate level in Stage 3 and Stage 4 of Chronic Kidney Disease (CKD) Patients
DOI:
https://doi.org/10.71395/ijhp.1.3.2024.3-7Abstract
Background and Objectives: Chronic kidney disease (CKD) disrupts acid-base balance, leading to metabolic acidosis. The impaired kidneys cannot remove acid effectively or reabsorb enough bicarbonate, resulting in low bicarbonate levels and metabolic acidosis. To evaluate the association of bicarbonate in patients among chronic kidney disease (CKD) stage 3 and stage 4. To evaluate the metabolic acidosis in the progression of chronic kidney disease (CKD).
METHODOLOGY: A retrospective study was conducted in the Department of Nephrology, Sheikh Zayed Hospital, Lahore, Punjab. The study was conducted during the 3 months from May to July, 2023. The study included a total of 150 patients diagnosed with chronic kidney illness. Among these individuals, 74 were found to have stage 3 CKD, while the remaining 76 were evaluated to have stage 4 CKD. Cobas C-311 and Microlab 300 were used to analyze bicarbonates level. A self-designed Performa was used to collect the patient data. Data were entered and analyzed by using excel and displayed by using Tables and Bar Charts.
RESULTS: In chronic kidney disease (CKD) stage 3, results indicated that 45% of male patients and 32% of female patients had normal serum bicarbonate levels ranging from 22 to 29 mEq/L, while the level was less than 22 mEq/L in 55% of males and 68% of females. According to the results from chronic kidney disease (CKD)
stage 4, 15% of male and 14% of female patients had normal serum bicarbonate levels ranging from 22 to 29 mEq/L, and 85% of male and 86% of female patients had a serum bicarbonate level < 22 mEq/L.
CONCLUSION: In conclusion, individuals with CKD, especially those in late stages, frequently have metabolic acidosis, which is characterized by low blood bicarbonate levels. This condition has been associated with higher mortality rates and greater risk of kidney disease progression.
References
Palomo AKG, Espinoza ET, Avalos JAJ, García JDC. Exosomal RNA in renal diseases. Exosomal RNA: Elsevier; 2024. p. 249-70.
Balcı AK, Koksal O, Kose A, Armagan E, Ozdemir F, Inal T, et al. General characteristics of patients with electrolyte imbalance admitted to emergency department. World journal of emergency medicine. 2013;4(2):113.
Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrology Dialysis Transplantation. 2009;24(4):1232-7.
Gnaiger E. Mitochondrial pathways and respiratory control: an introduction to OXPHOS analysis. Bioenergetics communications. 2020;2020:2-.
Ammirati AL. Chronic kidney disease. Revista da Associação Médica Brasileira. 2020;66(Suppl 1):3-9.
Wilson S, Mone P, Jankauskas SS, Gambardella J, Santulli G. Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk. The Journal of Clinical Hypertension. 2021;23(4):831-35.
Evans PD, Taal MW. Epidemiology and causes of chronic kidney disease. Medicine. 2011;39(7):402-6.
Almutary H, Bonner A, Douglas C. Symptom burden in chronic kidney disease: a review of recent literature. Journal of Renal care. 2013;39(3):140-50.
Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter TH. Treatment of chronic kidney disease. Kidney international. 2012;81(4):351-62.
Smáradóttir SM, Davíðsdóttir LL, Davíðsdóttir RF. Er vökvafasta fyrir skurðaðgerðir að breytast? Fræðileg samantekt.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of internal medicine. 2003;139(2):137-47.
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease–a systematic review and
meta-analysis. PloS one. 2016;11(7):65-69.
Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. American journal of kidney diseases. 2009;53(3):4-16.
Beynon-Cobb B, Louca P, Hoorn EJ, Menni C, Padmanabhan S. Effect of sodium bicarbonate on systolic blood pressure in CKD: a systematic
review and meta-analysis. Clinical Journal of the American Society of Nephrology. 2023;18(4):435-45.
Fukasawa H, Kaneko M, Uchiyama Y, Yasuda H, Furuya R. Lower bicarbonate level is associated with CKD progression and all-cause mortality: a propensity score matching analysis. BMC nephrology. 2022;23(1):86.
Dobre M, Yang W, Chen J, Drawz P, Hamm LL, Horwitz E, et al. Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. American Journal of Kidney Diseases. 2013;62(4):670-8.
Dobre M, Yang W, Pan Q, Appel L, Bellovich K, Chen J, et al. Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. Journal of the American Heart Association. 2015;4(4):e001599.
Kim HJ, Ryu H, Kang E, Kang M, Han M, Song SH, et al. Metabolic acidosis is an independent risk factor of renal progression in Korean chronic kidney disease patients: The KNOW-CKD study results. Frontiers in Medicine. 2021;8:70-75.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 International Journal of Healthcare Professions
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments ijhp@giu.edu.pk
